Sarepta Therapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 730.8M | 442.9M | 399.4M | 611.1M | 744.9M | 658.4M | 467.2M | 362.9M |
| Cost of Goods Sold | 119.4M | 398.7M | 150.8M | 152.6M | 137.6M | 132.3M | 91.7M | 44.5M |
| Gross Profit | 611.4M | 44.2M | 248.6M | 458.5M | 607.3M | 526.1M | 375.5M | 318.4M |
| R&D Expenses | 154.0M | 325.3M | 218.9M | 204.4M | 773.4M | 200.0M | 224.5M | 179.7M |
| Operating Expenses | 253.0M | 455.8M | 352.0M | 343.0M | 907.7M | 364.4M | 353.3M | 319.1M |
| Operating Income | 358.4M | -411.6M | -103.4M | 115.6M | -300.4M | 161.7M | 22.2M | -701K |
| Other Income / Gains | -15.3M | 133.3M | -90.7M | 38.1M | -83.1M | 10.1M | 11.8M | 14.3M |
| Net Income | 331.0M | -282.8M | -179.9M | 196.9M | -447.5M | 159.0M | 33.6M | 6.5M |
| EPS (Diluted) | 3.15 | -2.74 | -1.80 | 2.01 | -4.60 | 1.65 | 0.35 | 0.07 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.837 | 0.10 | 0.622 | 0.75 | 0.815 | 0.799 | 0.804 | 0.877 |
| General And Administrative Expenses | 109.0M | 128.3M | 91.9M | 137.9M | 133.6M | 163.9M | 128.2M | 138.8M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 109.0M | 128.3M | 91.9M | 137.9M | 133.6M | 163.9M | 128.2M | 138.8M |
| Other Expenses | -9.9M | 2.2M | 41.2M | 667K | 601K | 601K | 602K | 601K |
| Cost And Expenses | 372.4M | 854.5M | 502.7M | 495.5M | 1.05B | 496.7M | 445.0M | 363.6M |
| Interest Income | 7.0M | 8.4M | 8.4M | 7.1M | 12.4M | 14.7M | 18.3M | 18.8M |
| Interest Expense | 21.7M | 7.6M | 7.6M | 5.2M | 4.5M | 4.5M | 4.9M | 4.8M |
| Depreciation And Amortization | 10.6M | 5.3M | 18.4M | 10.8M | 10.0M | 10.5M | 9.8M | 8.7M |
| Ebitda | 375.5M | -252.2M | -168.0M | 169.7M | -369.0M | 186.7M | 48.7M | 27.1M |
| Ebitdaratio | 0.514 | -0.569 | -0.421 | 0.278 | -0.495 | 0.284 | 0.104 | 0.075 |
| Operating Income Ratio | 0.49 | -0.929 | -0.259 | 0.189 | -0.403 | 0.246 | 0.048 | -0.002 |
| Income Before Tax | 343.2M | -278.3M | -194.0M | 153.6M | -383.5M | 171.7M | 34.0M | 13.6M |
| Income Before Tax Ratio | 0.47 | -0.628 | -0.486 | 0.251 | -0.515 | 0.261 | 0.073 | 0.037 |
| Income Tax Expense | 12.2M | 4.6M | -14.1M | -43.3M | 64.0M | 12.7M | 395K | 7.1M |
| Net Income Ratio | 0.453 | -0.639 | -0.451 | 0.322 | -0.601 | 0.242 | 0.072 | 0.018 |
| Epsdiluted | 2.88 | -3.93 | -1.80 | 1.89 | -4.60 | 1.50 | 0.33 | 0.07 |
| Weighted Average Shs Out | 105.0M | 104.8M | 100.2M | 98.0M | 97.4M | 96.3M | 95.4M | 94.6M |
| Weighted Average Shs Out Dil | 121.9M | 104.8M | 100.2M | 106.6M | 97.4M | 108.5M | 100.4M | 99.1M |